Stuart Poulton and Patricia Judson (Karyopharm)

As long­time CMO ex­its, Karyopharm taps Big Phar­ma vets to steer can­cer drug fran­chise

As Richard Paul­son con­tin­ues to make a case for the Xpovio fran­chise, he will be sur­round­ing him­self with a new clin­i­cal team at Karyopharm.

The biotech re­vealed Tues­day that ex­ec­u­tive vice pres­i­dent and chief med­ical of­fi­cer Jatin Shah de­parts for “oth­er pro­fes­sion­al op­por­tu­ni­ties.” While CEO Paul­son looks for Shah’s re­place­ment, he has re­cruit­ed two Big Phar­ma vets to take up key posts on the team: Pa­tri­cia Jud­son, who led women’s on­col­o­gy at both Glax­o­SmithK­line and As­traZeneca, will be­come SVP of med­ical strat­e­gy; and Stu­art Poul­ton, for­mer­ly of Ab­b­Vie, Am­gen and Eli Lil­ly, has been ap­point­ed SVP of strat­e­gy and port­fo­lio man­age­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.